SPONSOR
ImmunityBio, Inc.
Total Trials
3
Recruiting
3
Phases
Phase 2, Phase 1, Phase 3
NCT06061809 Phase 2
Recruiting
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Glioblastoma
NCT06334991 Phase 1
Recruiting
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma Refractory/ Relapsed
NCT06745908 Phase 3
Recruiting
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
NSCLC Stage IV